Mitochondria-targeting particles

Amaraporn Wongrakpanich; Sean M Geary; Mei-ling A Joiner; Mark E Anderson; Aliasger K Salem

doi:10.2217/nnm.14.161

Back

Journal article

Peer reviewed

Mitochondria-targeting particles

Amaraporn Wongrakpanich, Sean M Geary, Mei-ling A Joiner, Mark E Anderson and Aliasger K Salem

Nanomedicine (London, England), Vol.9(16), pp.2531-2543

11/2014

DOI: 10.2217/nnm.14.161

PMCID: PMC4294695

PMID: 25490424

Files and links (1)

url

https://www.ncbi.nlm.nih.gov/pmc/articles/4294695View

Open Access

Abstract

Mitochondria are a promising therapeutic target for the detection, prevention and treatment of various human diseases such as cancer, neurodegenerative diseases, ischemia-reperfusion injury, diabetes and obesity. To reach mitochondria, therapeutic molecules need to not only gain access to specific organs, but also to overcome multiple barriers such as the cell membrane and the outer and inner mitochondrial membranes. Cellular and mitochondrial barriers can be potentially overcome through the design of mitochondriotropic particulate carriers capable of transporting drug molecules selectively to mitochondria. These particulate carriers or vectors can be made from lipids (liposomes), biodegradable polymers, or metals, protecting the drug cargo from rapid elimination and degradation in vivo. Many formulations can be tailored to target mitochondria by the incorporation of mitochondriotropic agents onto the surface and can be manufactured to desired sizes and molecular charge. Here, we summarize recently reported strategies for delivering therapeutic molecules to mitochondria using various particle-based formulations.

Drug Carriers - administration & dosage

Drug Delivery Systems

Humans

Liposomes - administration & dosage

Mitochondria - drug effects

Mitochondria - pathology

Nanoparticles - administration & dosage

Details

Title: Subtitle: Mitochondria-targeting particles
Creators: Amaraporn Wongrakpanich - Department of Pharmaceutical Sciences & Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA 52242, USA
Sean M Geary
Mei-ling A Joiner
Mark E Anderson
Aliasger K Salem
Resource Type: Journal article
Publication Details: Nanomedicine (London, England), Vol.9(16), pp.2531-2543
DOI: 10.2217/nnm.14.161
PMID: 25490424
PMCID: PMC4294695
NLM abbreviation: Nanomedicine (Lond)
ISSN: 1743-5889
eISSN: 1748-6963
Grant note: 1R21CA13345-01 / NCI NIH HHS 1R21CA128414-01A2/UI / NCI NIH HHS R21 CA128414 / NCI NIH HHS P30 CA086862 / NCI NIH HHS R21 CA133456 / NCI NIH HHS P50 CA097274 / NCI NIH HHS
Language: English
Date published: 11/2014
Academic Unit: Roy J. Carver Department of Biomedical Engineering; Pharmaceutical Sciences and Experimental Therapeutics; Biology; Craniofacial Anomalies Research Center; Biochemistry and Molecular Biology; Dental Research; Chemical and Biochemical Engineering
Record Identifier: 9984216606102771

Metrics

20 Record Views

75 Times Cited - Web of Science